Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

Neuroendocrine tumors (NETs) are difficult to treat due to their high heterogeneity and complexity. SEZ6 (Seizure-related 6 homolog) is a key regulator of dendritic formation and neural signaling and ...

Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug ...